摘要
目的评价氨溴索治疗新生儿肺炎的疗效和安全性。方法计算机检索pubMed、EMBsae、循证医学全文期刊、中国期刊全文数据库(CNKI)和维普中文科技期刊(VIP)等数据库,同时从纳入的文献中查找符合要求的随机对照试验并进行质量评价,采用RevMan5.0软件进行统计分析。结果最终符合入选标准的文献23篇,共纳入2 080例新生儿肺炎患者。纳入的研究按Jadad质量评价均为低质量研究。Meta分析结果显示,与对照组比较,氨溴索治疗组可以提高肺炎临床总有效率、改善症状体征和缩短住院时间,虽少数研究无统计学差异,但均显示出有益趋势。其漏斗图对称,不存在发表偏倚。检索的文献在安全性方面均描述为无明显药物不良反应。结论氨溴索治疗新生儿肺炎安全有效。但由于本次纳入的文献质量较低,仍需设计良好的随机双盲对照研究进行验证。
Objective To assess the effectiveness and safety of ambroxol for pneumonia in newborn infants. Methods We searched PubMed, EMBsae, Journals @ovid full text, CNKI and VIP databases for randomized controlled trials and evaluated the quality of them, then analyzed the data using Review Mnanager 5.0. Results Twenty-three RCTs involving 2080 patients of newborn were included. With Jadad scales, the trials are of low quality. The results of meta-analysis show that ambroxol can improve total improvement rate and symptoms, and shorten hospital stay when compared with the control group. Although statistical difference was not found in some comparisons, all trials showed beneficial tendency. The funnel plots were symmetrical, indicating no publication bias. All of the RCTs described ambroxol for pneumonia in neonates is safe. Conclusion The treatment of ambroxol for pneumonia in neonates is effective and safe. But because of the low quality of the RCTs, a well randomized doubleblind clinical trial is still required to further demonstrate and support the conclusion.
出处
《中国现代医生》
2013年第3期105-108,110,共5页
China Modern Doctor
